How to buy Gilead Sciences (GILD) shares in the UK

Gilead Sciences, Inc. is a biopharmaceutical company that focuses on researching and developing antiviral drugs to treat HIV, hepatitis B and hepatitis C, and Influenza. In October 2020, Gilead Sciences, Inc. bought immunomedics.

Gilead Sciences Inc (GILD) is a publicly traded drug manufacturers-general business based in the US. It opened the day at $62.51 after a previous close of $62.86. During the day the price has varied from a low of $62.165 to a high of $62.925. The latest price was $62.34 (25 minute delay). Gilead Sciences is listed on the NASDAQ and employs 14,400 staff. All prices are listed in US Dollars.

How to buy shares in Gilead Sciences

  1. Choose a platform. If you're a beginner, our share-dealing table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: GILD in this case.
  5. Research Gilead Sciences shares. The platform should provide the latest information available.
  6. Buy your Gilead Sciences shares. It's that simple.
The whole process can take as little as 15 minutes. You'll need a smartphone or computer, an internet connection, your passport or driving licence and a means of payment.

Fees for buying 10x Gilead Sciences shares with popular platforms

Both exchange rates and share prices fluctuate in real time, so the costs presented here should be considered as a guide only. They do not incorporate stamp duty. Always refer to the platform itself for availability and pricing – which may differ from our information.

Platform Platform fee Min. initial deposit Trading fee estimate
eToro Free Stocks logo £0 $10 £2.88
£578.96 total
Capital at risk
IG Share Dealing logo £0 £250 £12.17
£588.25 total
Capital at risk
Fineco logo £0 No minimum £5.76
£581.84 total
Capital at risk
Hargreaves Lansdown Fund and Share Account logo £0 £1 £17.71
£593.79 total
Capital at risk
Degiro Share Dealing logo £0 £0.01 £0.58
£576.66 total
Capital at risk
Freetrade logo £0 £1 £2.59
£578.68 total
Capital at risk
interactive investor Trading Account logo £9.99 per month No minimum £16.63
£592.72 total
Capital at risk
Stake logo £0 £50 £2.88
£578.96 total
Capital at risk
Halifax Share Dealing Account logo £36 per year £20 £16.70
£592.78 total
Capital at risk

Full comparison of share dealing platforms

Gilead Sciences share price (NASDAQ:GILD)

Use our graph to track the performance of GILD stocks over time.

Gilead Sciences price performance over time

Historical closes compared with the last close of $62.34

1 week (2022-09-20) -3.47%
1 month (2022-08-26) -0.05%
3 months (2022-06-27) -0.78%
2 years (2020-09-25) 0.14%
3 years (2019-09-27) -0.89%
5 years (2017-09-27) -25.66%

Is it a good time to buy Gilead Sciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

eToro Free Stocks

Invest in Gilead Sciences shares with 0% commission

  • Start investing from as little as $10
  • Pay no stamp duty on UK shares
  • Join 25 million users who trust their investments with eToro
Other fees apply. Capital at risk

All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.

Is Gilead Sciences under- or over-valued?

Valuing a stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of overall performance. However, analysts commonly use some key metrics to help gauge value.

P/E ratio

Gilead Sciences's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 20x. In other words, Gilead Sciences shares trade at around 20x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

However, Gilead Sciences's P/E ratio is best considered in relation to those of others within the drug manufacturers-general industry or those of similar companies.

PEG ratio

Gilead Sciences's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.5518. A PEG ratio below 1 can be interpreted as meaning the shares are not overvalued given the current rate of growth.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Gilead Sciences's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

However, it's sensible to consider Gilead Sciences's PEG ratio in relation to those of similar companies.


Gilead Sciences's EBITDA (earnings before interest, taxes, depreciation and amortisation) is a whopping $13.2 billion (£12.2 billion).

The EBITDA is a measure of a Gilead Sciences's overall financial performance and is widely used to measure a its profitability.

To put that into context you can compare it against similar companies.

Environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Gilead Sciences.

Total ESG risk score

Gilead Sciences's total ESG risk: 22.15

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Gilead Sciences's overall score of 22.15 (as at 01/01/2019) is pretty good – landing it in it in the 31st percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Gilead Sciences is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

To gain some more context, you can compare Gilead Sciences's total ESG risk score against those of similar companies.

Environmental score

Gilead Sciences's environmental score: 0.53/100

Gilead Sciences's environmental score of 0.53 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Gilead Sciences is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Social score

Gilead Sciences's social score: 12.97/100

Gilead Sciences's social score of 12.97 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Gilead Sciences is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Governance score

Gilead Sciences's governance score: 7.65/100

Gilead Sciences's governance score puts it squarely in the 2nd percentile of companies rated in the same sector. That could suggest that Gilead Sciences is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Controversy score

Gilead Sciences's controversy score: 2/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. A high-profile company, Gilead Sciences scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Gilead Sciences has, for the most part, managed to keep its nose clean.

Wondering how that compares? Below are the controversy scores of similar companies.

Environmental, social, and governance (ESG) summary

Gilead Sciences Inc was last rated for ESG on: 2019-01-01.

Total ESG score 22.15
Total ESG percentile 30.98
Environmental score 0.53
Environmental score percentile 2
Social score 12.97
Social score percentile 2
Governance score 7.65
Governance score percentile 2
Level of controversy 2

Gilead Sciences shares at a glance

Information last updated 2022-09-26.
Previous close$62.86
Change %-0.8272%
Information last updated 2022-09-20.
52-week range$55.2732 - $71.4734
50-day moving average$63.0878
200-day moving average$63.8468
Wall St. target price$70.78
PE ratio20.1284
Dividend yield$2.88 (4.44%)
Earnings per share (TTM)$3.27

Gilead Sciences share dividends


Dividend yield: 4.44% of stock value


Forward annual dividend yield: 4.44% of stock value


Dividend payout ratio: 41.19% of net profits

Gilead Sciences has recently paid out dividends equivalent to 4.44% of its share value annually.

Gilead Sciences has paid out, on average, around 41.19% of recent net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 4.44% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), shareholders could enjoy a 4.44% return on their shares, in the form of dividend payments. In Gilead Sciences's case, that would currently equate to about $2.88 per share.

While Gilead Sciences's payout ratio might seem fairly standard, it's worth remembering that it may be investing much of the rest of its net profits in future growth.

Gilead Sciences's most recent dividend payout was on 29 September 2022. The latest dividend was paid out to all shareholders who bought their shares by 14 September 2022 (the "ex-dividend date").

Gilead Sciences's dividend yield is perhaps best considered in relation to those of similar companies.

Share price volatility

Over the last 12 months, Gilead Sciences's shares have ranged in value from as little as $55.2732 up to $71.4734. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Gilead Sciences's is 0.328. This would suggest that Gilead Sciences's shares are less volatile than average (for this exchange).

To put Gilead Sciences's beta into context you can compare it against those of similar companies.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site